By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a clinical study evaluating SHR-1316 (sc) in combination with carboplatin and etoposide for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
SHR-1316 (sc) Overview
SHR-1316 (sc) is a subcutaneous formulation of Hengrui Pharma’s anti-PD-L1 monoclonal antibody (mAb). The intravenous formulation, adebrelimab (SHR-1316), received approval in China in March 2023 for use in combination with carboplatin and etoposide as first-line treatment for ES-SCLC.
Global Registration Context
Similar products, such as Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), are registered in the UK, European Union, the US, and other regions, highlighting the potential of subcutaneous formulations in expanding treatment options for patients with ES-SCLC.-Fineline Info & Tech